At the genetic level, several alterations have been reported as key in PCa, such as TMPRSS2-ETS fusions, amplification of the MYC oncogene, mutations or amplification of AR, and mutations or deletions of PTEN and TP53 [48]. The gene discussed is TP53; the disease is posterior cortical atrophy.